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Abstract: Smoking is still the most prominent cause of preventable premature death in 
the United States and an increasing cause of morbidity and mortality throughout the world. 
Although the current treatments such as nicotine replacement therapy (NRT) and bupropion are 
effective, long-term abstinence rates are low. Mechanism studies suggest that the pleasurable 
effects of smoking are mediated predominantly by nicotine, which activates the brain reward 
system by activation of brain α4β2 nicotinic acetylcholine receptors (nAChRs). Varenicline is 
a novel α4β2 nAChR partial agonist and has been found to be even more effective than NRT or 
  bupropion in attenuating smoking satisfaction and in relieving craving and withdrawal symptoms 
after abstinence. Thus, varenicline has been recently approved to be a first-line medication 
for smoking cessation in the United States and European countries. Varenicline is generally 
well tolerated in healthy adult smokers, with the most commonly reported adverse effects being 
nausea, insomnia, and headache. However, growing postmarketing data has linked varenicline 
to an increase in neuropsychiatric symptoms such as seizures, suicidal attempts, depression, and 
psychosis as well as serious injuries potentially relating to unconsciousness, dizziness, visual 
disturbances, or movement disorders. Therefore, new safety warnings are issued to certain high 
risk populations, such as patients with mental illness and operators of commercial vehicles and 
heavy machinery. In particular, pilots, air traffic controllers, truck and bus drivers have been 
banned from taking varenicline.
Keywords: nicotine, varenicline, α4β2 nicotinic acetylcholine receptor, nAChRs, partial 
agonist, smoking cessation
Introduction
It is estimated that about 1.3 billion people smoke cigarettes worldwide and about 
500 million people die annually from tobacco-related diseases.1–3 In the United States 
(US), about 45 million adults (∼20%) smoke cigarettes or are exposed to secondhand 
smoking, resulting in about 18% of total mortality and 440,000 annual premature 
deaths.1,2 The annual economic cost of smoking in the US is about 200 billion dollars. 
Smoking cessation has shown to significantly reduce the risk of many smoking-related 
diseases such as lung cancer, chronic lung diseases, myocardial infarction, and stroke 
as well as decrease morbidity and mortality related to tobacco use.3
However, tobacco dependence is a chronic relapse disorder that is difficult to treat.3 
Despite the availability of effective pharmacologic aids, such as nicotine replacement 
therapy (NRT) and bupropion sustained-release, these treatments only help 5%–15% 
of people to maintain long-term abstinence from smoking.4–6 Craving and withdrawal 
symptoms after tobacco cessation are the most important reasons to prevent smokers Drug, Healthcare and Patient Safety 2010:2 40
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from achieving long-term tobacco abstinence. For these 
reasons, novel pharmacotherapies are being developed in 
an attempt to improve long-term abstinence outcomes. 
Among the most promising of treatments is varenicline, a 
novel partial α4β2 nicotinic acctylcholine receptors (nAChR) 
agonist, which has recently been approved by the US Food 
and Drug Administration (FDA) as a smoking cessation aid. 
Varenicline has been found to be even more effective than 
placebo, NRT or bupropion in clinical trials.5,6 In this article, 
we review the mechanism-based medication development 
strategies, preclinical pharmacology, efficacy, and safety 
profiles of varenicline in the treatment of cigarette smoking 
in humans.
Mechanism of tobacco dependence
The mechanisms underlying tobacco addiction are not 
  completely understood. Accumulating evidence indicates that 
nicotine is the major addictive component in tobacco.7 Nicotine 
binds to central and peripheral nAChRs. Acetylcholine (Ach) 
is an endogenous neurotransmitter that binds to and acti-
vates both nAChRs and muscarinic acetylcholine receptors. 
  Neuronal nAChRs are ligand-gated ion channels with high 
permeability to Ca++, and are formed from combinations of 
five subunits.8,9 To date, twelve different neuronal nAChR 
subunits have been cloned, including nine α-subunits 
(α2–α10) and three β-subunits (β2–β4). Non-neuronal 
  subunits, α1, β1, γ, δ, and ε, form peripheral nicotinic 
  receptors at the neuromuscular junction.10 The neuronal sub-
units combine with two α- and three β-, or five α7-subunits to 
form nAChRs (Figure 1).10,11 Both the α4β2 and α7 subtypes 
of nAChRs are the most abundant subtypes in the brain and 
are localized on presynaptic terminals,  somatodendrites, and 
  postsynaptic cells.8,9 Activation of presynaptic nAChRs by 
ACh or nicotine potentiates neurotransmitter release, while 
activation of postsynaptic nAChRs increases excitability of 
  postsynaptic cells by increasing influx of Na+ and Ca++ via 
nAChR channels.10–12
One third of the α4β2 nAChRs are located on the 
  dopamine (DA) cells in the mesolimbic DA system 
(Figure 1).13,14 This system originates from DA neurons 
in the ventral tegmental area (VTA) in the midbrain and 
projects to the forebrain nucleus accumbens (NAc) and 
the prefrontal cortex (PFC).15 The α4β2 nAChR subtype 
has been thought to play a vital role in mediating nicotine 
reward.8–10 This is supported by the finding that blockade of 
α4β2 nAChRs by dihydro-β-erythroidine (DHβE) inhib-
its nicotine self-administration in rats.16 Genetic deletion 
of α4 or β2 subunits largely abolishes nicotine binding 
to mouse brain and inhibits nicotine self-administration 
and nicotine-induced increases in NAc DA.17,18 Similarly, 
nicotine-mediated currents from VTA (DA) neurons are also 
inhibited by DHβE17,19 or dramatically decreased on midbrain 
neurons in β2-kockout mice.17,19,20 These data suggest that 
both the behavioral and DA-releasing effects of nicotine are 
Cingulate
Dorsal striatum
VTA
α4β2nAChR
NAc
PFC Out
In
Nicotine Na+/Ca++
α4
α4
β2
β2 β2
Figure 1 Schematic diagram of the mesolimbic DA projection pathway in human brain, illustrating that nicotine activates α4β2 nAChRs located on DA neurons in the VTA 
and increases VTA DA neuron activity as well as DA release in the NAc, dorsal striatum, and PFC. Insert: Simplified structure of α4β2 nAChR (ion channel) located on surface 
of VTA DA neurons. Activation of α4β2 nAChR opens the receptor ion channel, causing influx of Na+ and/or Ca++ and depolarization of VTA DA neuron.
Abbreviations: DA, dopamine; NAc, nucleus accumbens; nAChR, nicotinic acetylcholine receptors; PFC, prefrontal cortex; VTA, ventral tegmental area.Drug, Healthcare and Patient Safety 2010:2 41
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mediated predominantly by activation of α4β2 nAChRs in 
the mesolimbic DA system.8,9,17,21 As stated above, the α4β2 
nAChR is a receptor ion channel with high affinity to nicotine. 
High concentrations of nicotine binds to the α4β2 receptor, 
causing the ion channel opening and Na+ influx, which sub-
sequently depolarizes VTA DA neurons and increases DA 
release in the NAc (Figure 1).21
Medication strategies for the 
treatment of nicotine addiction
Modulating nAChRs can be achieved using nAChR agonists, 
antagonists, or partial agonists. Full agonists, such as 
NRT, mimic the effects of nicotine by activating the receptor, 
therefore reducing withdrawal symptoms during nicotine 
abstinence.22 NRT is proven effective in smoking cessation,23 
although it does not produce complete abstinence because 
the smoker is still physically dependent on the effects of 
smoking. Antagonists, such as mecamylamine, compete with 
nicotine or ACh for occupancy of the receptors.24 Therefore, 
a full antagonist may fully block the pharmacological action 
of nicotine, such as nicotine reward. However, antagonists 
are prone to induce withdrawal symptoms by themselves.22 
Surprisingly, mecamylamine in combination with NRT is 
more effective than NRT alone or mecamylamine alone in 
smoking cessation.25,26 This could be due to a functional effect 
of the agonist NRT (reduction of the withdrawal syndromes) 
in combination with the effect of the antagonist mecamyla-
mine (attenuation of the reinforcing effects of nicotine). This 
finding suggests that the development of a nicotine partial 
agonist such as cytisine and varenicline may be optimal in 
the treatment of nicotine dependence because partial agonists 
display the properties of both agonists and antagonists. Partial 
agonists occupy the receptors, but only partially activate them. 
As a consequence, the action of a partial agonist is dependent 
on the receptor occupancy.27 In cigarette smokers, a partial 
agonist would mostly work as an antagonist during smoking 
(ie, high nicotine occupancy), but as an agonist during absti-
nence or withdrawal (ie, low nicotine occupancy). Thus, the 
rewarding effects of smoking would decrease substantially 
but not disappear completely, whereas withdrawal symptoms 
and craving episodes would occur less frequently during drug 
abstinence due to the release of a low-to-moderate level of 
DA produced by a partial agonist itself.28–30
Cytisine – an unnoticed smoking 
cessation drug since the 1960s
Cytisine has a molecular structure somewhat similar to that 
of nicotine and varenicline (Figure 2). Cytisine is a natural 
insecticide present in plants called Cytisus laburnum (Golfen 
Rain).28 Cytisine (Tabex®; Sopharma, Sofia, Bulgaria) has 
been used in Bulgaria, Germany, Poland, and Russia as 
a smoking cessation aid since the 1960s.29–32 Despite its 
widespread use in Eastern and Central Europe, cytisine has 
remained largely unnoticed elsewhere, possibly due to limited 
access to the non-English literature.32 In addition, the underly-
ing mechanisms have remained unclear until the 1990s when 
it was reported that cytisine is a partial agonist of nAChRs 
with high affinity for α4β2 receptors.28,33 Behavioral stud-
ies in experimental animals suggest that cytisine produces 
low-to-moderate behavioral activation,34,35 conditioned place 
preference,36 and drug discriminative effects.37 In addition, 
drug-naive mice also self-administer cytisine intravenously, 
suggesting that cytisine has certain reinforcing effects.38
Preclinical pharmacology  
of varenicline
Varenicline as a smoke-cessation aid was developed by 
Pfizer in 1997, largely based on cytisine described above.39,40 
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Figure 2 Chemical structures of nicotine, cytisine, and varenicline.Drug, Healthcare and Patient Safety 2010:2 42
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In vitro binding assays indicate that varenicline has higher 
  binding affinity (Ki = 0.15 nM) to α4β2 nAChRs than 
cytisine (Ki = 0.23 nM) or nicotine (Ki = 1.6 nM). It has 
500–20,000-fold selectivity for α4β2 receptors over other 
nAChR subtypes (Table 1).39–41 In vitro functional patch 
clamp studies in HEK cells expressing nAChRs show 
that varenicline is a partial agonist with 45% of nicotine’s 
  maximal efficacy at α4β2 nAChRs.39 In neurochemical 
  models varenicline has significantly lowered (40%–60%) 
efficacy than nicotine in stimulating [3H]-DA release from 
rat brain slices in vitro, and in increasing DA release from 
rat NAc in vivo.39 When combined with nicotine, varenicline 
effectively attenuates the nicotine-induced DA release, 
  consistent with partial agonism.39
In animal models of addiction (Table 2), varenicline 
significantly inhibits nicotine self-administration,39 nicotine-
enhanced brain stimulation reward,42 and nicotine priming, 
but not nicotine-associated cue-induced reinstatement of 
drug-seeking behavior.43 Varenicline itself does not induce 
reinstatement of nicotine seeking when administered as 
a priming injection.43 Varenicline partially substitutes for 
nicotine in self-administration testing in animals and partially 
generalizes to nicotine in the drug discrimination preclinical 
animal paradigm,39,44 suggesting that it may have some 
abuse potential, but lower than that of nicotine. In addition, 
  varenicline also enhanced the basal locomotor activity in 
drug-naive rats by itself, while pretreatment with varenicline 
attenuated acute nicotine-induced hyperlocomotion and 
repeated nicotine-induced behavioral sensitization.45
In addition to being an α4β2 nAChR partial agonist, 
varenicline is also a full α7 nAChR agonist.46 To determine 
which receptor subtype underlies the action of varenicline, 
we have recently investigated the effects of α4β2 or α7 
receptor agonists or antagonists on varenicline-enhanced 
electrical brain-stimulation reward (BSR). We found 
that systemic administration of nicotine or varenicline 
  produced significant BSR enhancement, while pretreatment 
with varenicline dose-dependently attenuated nicotine-
enhanced BSR. The BSR-enhancing effect produced by 
varenicline was blocked by mecamylamine (a full nAChR 
antagonist) and DHβE (a selective α4-containing nAChR 
antagonist), but not by methyllycaconitine (a selective 
α7 nAChR antagonist), suggesting an effect mediated 
by activation of α4β2 receptors.42 This suggestion is 
further supported by findings that SIB-1765F, another 
  selective α4β2 nAChR agonist, produced a dose-dependent 
  enhancement of BSR, while pretreatment with SIB-1765F 
also attenuated nicotine-enhanced BSR. In contrast, the 
selective α7 receptor agonist, ARR-17779, altered neither 
BSR itself nor nicotine-enhanced BSR, at any dose tested.42 
These findings are consistent with other reports that neither 
deletion of α7 receptors nor pharmacological blockade of 
α7 receptors alters the nicotine-produced discriminative 
stimulus effect.47–49 Together, these data suggest that the 
pharmacotherapeutic effects of varenicline on nicotine’s 
action are mediated by activation of the α4β2, rather than 
the α7 nAChR subtype.
The bioavailability of varenicline is high and is unaffected 
by the time of dosing or administration with food.50 After 
serial measurements, varenicline followed first-order kinetics, 
with an elimination T1/2 of ∼24 h after single and multiple 
doses.50,51 Steady-state levels were achieved within four 
days with repeated oral dosing.51 Pharmacokinetic assays 
in healthy adult smokers indicated that varenicline did not 
undergo significant hepatic metabolism. Varenicline is 20% 
plasma protein bound. Its clearance is predominantly renal, 
with 90% excreted unchanged in the urine. Elimination 
of varenicline by the kidney primarily involves glomerular 
filtration and active tubular secretion via the renal organic 
cation transporter hOCT2.51,52
Therapeutic efficacy in humans
Following promising results in preclinical studies, together 
with a strong theoretical foundation for its use, testing 
of varenicline began in clinical safety and efficacy trials. 
Table 3 summarizes the results of the ten clinical trials 
with varenicline since it was approved by the US FDA in 
2006. These trials were conducted in Australia, Canada, 
Europe, Japan, South Korea, China, Thailand, Singapore, 
and the US, and enrolled both male and female subjects 
Table 1 In vitro binding affinity and functional activity of nicotine, cytisine, and varenicline at human brain nAChRs28,29,41
α4β2a (Ki, nM) α3β4b (Ki, nM,) α7c (Ki, nM) α1β1γδd (Ki, nM) Functional activity 
at α4β2e
Nicotine 1.6 530 6,300 6,300 –
Cytisine 0.23 840 4,200 250 56%
Varenicline 0.15 83.2 616.6 3,388.4 45%
Notes: a[3H]-Nicotine, b[3H]-Epibatidine, c[125I]-α-Bungarotoxin, d[125I]-α-Bungarotoxin, e% Response of 10 µM cytisine or varenicline relative to 10 µM (-)-nicotine.Drug, Healthcare and Patient Safety 2010:2 43
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(age range, 18–75 years) with no major comorbidities in the 
past year. The primary end point in most of the studies was 
efficacy, which was assessed primarily in terms of the con-
tinuous abstinence rate (CAR) or continuous quit rate (CQR) 
based on subjective reporting and confirmation by exhaled 
carbon monoxide (CO) measurement (10 ppm). The second 
end points included the urge to smoke, withdrawal symptoms, 
and the reinforcing effects of nicotine. In addition, odds ratio 
(OR) meta-analysis was also used to measure the comparative 
efficacy and abstinence rates for various smoking cessation 
medications in some of those clinical trials.
One of the trials reported follow-up data to 24 weeks,53 
and the others reported data to 52 weeks.54–62 During treatment 
with oral varenicline titrated to 1 mg twice per day (bid), 
CO-confirmed CQRs or CARs at week 12 ranged from 
28.8% to 65.4%, at week-24 from 20.8% to 70.5%, and at 
week-52 from 14.4% to 43.6%. In all these trials, varenicline 
1 mg bid was associated with significantly higher CARs or 
CQRs compared with placebo at either week 12, week 24, or 
week 52 when compared with placebo. Three trials reported 
significantly higher CARs or CQRs with varenicline 1 mg 
bid compared to bupropion,55,57,58 and one trial reported 
significantly higher CARs with varenicline compared with 
NRT (Table 3).62 In a relapse-prevention study, CARs were 
significantly improved at 24 weeks with varenicline relative 
to placebo (70.5% vs 49.6%).59
Nides et al63 conducted a pooled data analysis from the 
Phase III trials by Gonzales et al57 and Jorenby et al58 to 
explore the relative efficacy of varenicline, bupropion, and 
placebo for smoking cessation. Pooled CARs for weeks 9 
through 12 were significantly greater for varenicline com-
pared with bupropion and placebo (44.0%, 29.7%, and 
17.7%, respectively; both comparisons P  0.001).
West et al64 conducted a similar analysis of pooled 
data from the same two Phase III trials57,58 to evaluate 
the effects of varenicline, bupropion, and placebo on 
  craving and withdrawal symptoms among smokers. They 
used the Minnesota Nicotine Withdrawal Scale (MNWS) 
to score craving and withdrawal symptoms in abstinent 
smokers (n = 612) and the Modified Cigarette Evaluation 
  Questionnaire (mCEQ) to score the reinforcing effects of 
smoking in nonabstinent smokers (n = 1,115). They found 
that among all participants, cravings (urge to smoke) were 
significantly reduced with varenicline or bupropion com-
pared with placebo (both P  0.001) and with varenicline 
compared with bupropion (P = 0.008). Overall, varenicline 
or bupropion significantly inhibited negative withdrawal syn-
dromes (depression, irritability, anxiety, difficulty concentrat-
ing, and insomnia) compared with placebo. In addition, they 
also found that varenicline-treated patients had significantly 
lower pleasurable effects of smoking compared with those 
treated with bupropion and placebo, as assessed by mCEQ 
scores for smoking satisfaction, psychological reward and 
enjoyment of respiratory tract sensations.
Cahill et al65 conducted a systemic review and meta-
analysis of the efficacy and tolerability of varenicline for 
Table 2 Behavioral effects of cytisine and varenicline in animal models related nicotine addiction
Animal models Cytisine Varenicline
Locomotor behavior ↑ Locomotion ↑ Locomotion by itself45
by itself  34,35 ↓ Nicotine-induced hyperactivity45
↓ Nicotine-induced sensitization45
Self-administration Naïve mice self- ↓ Nicotine SA39
(SA) administer cytisine38 No effect on food taking39
Supports low SA by itself39,43
Brain-stimulation reward (BSR) ↑ BSR by itself42
­ – ↓ Nicotine-enhanced BSR42
Reinstatement ↓ Nicotine-induced reinstatement43
– But not on cue-induced reinstatement43
No reinstatement by itself43
Condition place preference (CPP) Intra-VTA cytisine
produces CPP36 –
Drug discrimination (DD) Producing DD by itself Fully substitutes nicotine in DD39
Partially substitutes nicotine in DD37
Dopamine (DA) in the ↑ DA by itself39
nucleus accumbens – ↓ Nicotine-enhanced DA39Drug, Healthcare and Patient Safety 2010:2 44
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smoking cessation in seven placebo-controlled trials, one 
relapse-prevention trial, and one open-label trial comparing 
varenicline with NRT. The nine trials covered 7,267 
  participants, 4,744 of whom used varenicline. The pooled 
ORs for CAR for varenicline versus placebo at six months or 
longer was 2.33 (95% confidence interval [CI]: 1.95–2.80), 
for varenicline versus bupropion at one year was 1.52 (95% 
CI: 1.22–1.88), and for varenicline versus NRT at one year 
was 1.31 (95% CI: 1.01–1.71). These data suggest that var-
enicline is even more effective than bupropion or NRT.
Mills et al66 conducted large-scale pooled data analysis 
from nine trials with varenicline (n = 5,192), 101 clinical 
trials with NRT (n = 31,321), and 31 trials with bupropion 
(n = 11,118) in order to compare treatment effects across 
interventions. They found that the pooled ORs for smoking 
cessation at four weeks post-target quit data with varenicline, 
NRT, and bupropion were 3.16, 2.25, and 2.05, respectively 
(P  0.001, compared to placebo). Two trials evaluated head 
to head comparisons of varenicline and bupropion, and found 
a pooled OR 1.86 (P  0.001). Indirect comparison between 
Table 3 Clinical efficacy (CARs) of varenicline in human clinical trials
Varenicline dose CARs (%)  
(Week 12)
CARs (%)  
(Week 24)
CARs (%)  
(Week 52)
Nides et al55  
(n = 638)
Placebo  
0.3 mg/d, 6 wks  
1 mg/d, 6 wks  
1 mg, bid, 6 wks  
Bupropion:  
150 mg, bid, 6 wks
10.6  
16.7  
15.1  
28.8**  
19.8*
7.3  
9.5  
9.5  
20.8**  
10.3
4.9  
7.9  
5.6  
14.4**  
6.3
Oncken et al56  
(n = 1,210)
Placebo  
0.5 mg/d, 12 wks  
(Titrated)  
0.5 mg, bid, 12 wks  
(Nontitrated)  
1 mg, bid, 12 wks  
(Titrated)  
1 mg, bid  
(Nontitrated)
11.6  
40.8***  
47.3***  
54.6***  
44.2***
–  
–  
–  
–  
–
3.9  
Pooled (Titrated   
and Nontitrated):   
18.5***  
Pooled (Titrated   
and Nontitrated):   
22.4***
Gonzales et al57  
(n = 1,025)
Placebo  
1 mg, bid, 12 wks  
Bupropion:  
150 mg, bid
17.7  
44.0***  
29.5***
10.5  
29.5***  
20.7***
8.4  
21.9***  
16.1***
Jorenby et al58  
(n = 1,027)
Placebo  
1 mg, bid, 12 wks  
Bupropion:  
150 mg, bid, 12 wks
17.6  
43.9***  
29.8***
13.2  
29.7***  
20.2**
10.3  
23***  
14.6
Tonstad et al59  
(n = 1,210)
Placebo  
1 mg, bid, 12 wks
– 
–
49.6  
70.5***
36.9  
43.6*
Tsai et al53  
(n = 250)
Placebo  
1 mg, bid, 12 wks
32.3  
59.5***
21.8  
46.8***
Nakamura et al60  
(n = 619)
Placebo  
0.25 mg, bid, 12 wks  
0.5 mg, bid, 12 wks  
1 mg, bid, 12 wks
39.5  
54.7*  
55.5**  
65.4***
29.5  
33.6  
35.2  
37.7
23.3  
27.3  
28.9  
34.6
Niaura et al61  
(n = 320)
Placebo  
0.5–2 mg/d, 12 wks
11.6  
40.1***
9  
28***
7.7  
22.3***
Aubin et al62  
(n = 757)
NRT, 21 mg/d, 6 wks  
1 mg, bid, 12 wks
42.2  
55.6###
26.6  
32.2
19.8  
25.9#
Wang et al67  
(n = 333)
Placebo  
1 mg, bid, 12 wks
– 
–
31.6  
50.3***
25  
38.2**
Notes: ***P  0.05, **P  0.01, *P  0.001, compared to placebo; #P  0.05, ###P  0.001, compared to NRT.Drug, Healthcare and Patient Safety 2010:2 45
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varenicline and NRT was OR 1.56 (P  0.001), and between 
varenicline and bupropion OR 1.40 (P = 0.01).
Taken together, all these clinical data suggest that 
  varenicline is superior to placebo, NRT, and bupropion 
for achieving abstinence from smoking in the short-term. 
Varenicline not only significantly attenuates the craving and 
withdrawal symptoms that occur during abstinence from 
smoking, but also significantly reduces the rewarding effects 
of nicotine and delay smoking relapse. Thus, varenicline, as 
the newest agent approved for smoking cessation, offers a new 
  therapeutic option for the treatment of nicotine addiction.
Tolerability
Varenicline is generally well tolerated, with the most 
  commonly reported adverse effects being nausea (28.8%, 
9.9%, and 9.1%), insomnia (14.2%, 21.5%, and 12.6), and 
headache (14.2%, 11.1%, and 12.4) when compared to 
bupropion or placebo.54
Nausea
Mild to moderate nausea was the most frequently reported 
adverse effect (overall incidence, 24.4%–52.0%) that 
occurred at a higher rate in varenicline group than in placebo 
groups. Most episodes of nausea began in the first week of 
treatment and lasted for a median duration of 12 days. Dose 
titration appeared to reduce the overall incidence of nausea.56 
There was a low incidence of nausea (13.4%) in varenicline-
treated patients in the self-regulated flexible dosing study.61 In 
clinical trials, rates of treatment discontinuation due to nausea 
were generally 5% in varenicline-treated patients.54
Insomnia
Insomnia was another commonly reported adverse effect 
(14.0%–37.2%) associated with varenicline in the clinical 
trials.5,54 In general, insomnia occurred during the first four 
weeks of treatment with varenicline and became less common 
as treatment continued. In one extended treatment study,67 the 
incidence of insomnia was 19.1% with varenicline and 9.5% 
with placebo, suggesting that insomnia may be a common 
symptom of nicotine withdrawal during smoking-cessation 
attempts.
Headache
Other common adverse effects include headache, abnormal 
dreams, sleep disturbance, dizziness, dry mouth, increased 
appetite, weight gain, and constipation, which generally 
occurred at rates twice those with placebo.55–67 These adverse 
events were mild-to-moderate and transient, occurring 
  predominantly during the first four weeks of therapy. The 
rates of discontinuation of varenicline treatment due to these 
adverse effects were 2% of participants.
Utility in high risk people
Since the approval of varenicline in May 2006, post-marketing 
surveillance suggests an association between varenicline and 
increased risk of erratic behavior, agitation, suicidal attempt, 
depression, psychosis, and severe injuries.68 While some of 
the behavioral and mood changes may be associated with 
nicotine withdrawal, some occurred in people who continued 
smoking while on the medication. The Institute for Safe 
Medication Practices (ISMP), an independent safety group, 
analyzed all adverse effects since the approval for marketing 
and found that varenicline accounted for more reports of 
serious adverse effects than any other drug in the US.69,70 
Accordingly, the following people are thought to be high-risk 
to the use of varenicline.
Patients with mental illnesses
In the fourth quarter report of 2007,71 the FDA reported that 
among the total 988 serious injuries related to varenicline 
from 2006 to December 2007, there were 227 reports of 
suicidal attempt or behavior, 397 cases of possible psychosis, 
and 525 reports of hostility or aggression within days to 
weeks of initiating varenicline therapy for smoking cessation. 
Based on these reports, in November 2007, the FDA issued 
an early alert about the safety of varenicline, emphasizing the 
need for screening for pre-existing psychiatric illness before 
using varenicline and the importance of monitoring/reporting 
of mood or behavior changes.71 In May 2008, the FDA 
updated the previous Public Health Advisory and required 
that all patients should be observed and report to their 
  physicians immediately for any mood or behavior changes, or 
worsening of preexisting psychiatric illness, during or upon 
discontinuation of varenicline therapy.72 This safety concern 
in such high-risk patients was further emphasized in more 
recent clinical reports.73–76 For example, about 5% patients 
(from the total 2,682 patients since December 2006) in the 
UK reported psychiatric effects during treatment with vareni-
cline, including sleep disorder (43, 1.6%), anxiety (33, 1.2%), 
depression (29, 1.0%), abnormal dreams (26, 1.0%), mood 
change (17, 0.6%), and suicidal events (n = 5).77
Commercial vehicle drivers  
and heavy machinery operators
In addition to those psychiatric effects described above, in the 
fourth quarter report of 2007,71 the FDA also reported 372 Drug, Healthcare and Patient Safety 2010:2 46
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movement disorders, 173 serious accidental injuries (includ-
ing 28 traffic accidents and 77 falls), at least 148 reports of 
visual disturbances, 224 reports of potential cardiac rhythm 
disturbances, 338 moderate to severe skin reactions, and 
numerous reports of drowsiness that may affect patients’ abil-
ity to drive or operate machinery. Based on these reports, the 
ISMP issued immediate safety concerns related to varenicline 
use among operators of vehicles and heavy machinery as 
well as in any setting in which alertness and motor control 
are required to avoid serious injury. In May 2008, the Federal 
Motor Carrier Safety Administration and Federal Aviation 
Administration announced that pilots, air-traffic controllers, 
and truck and bus drivers are barred from taking smoking-
cessation drug.78,79
Conclusions
Varenicline (Chantix®; Pfizer, New York, NY), an α4β2 
nAChR partial agonist, is the first in a new class of agents 
for smoking cessation. In the updated clinical practice 
guideline from the US Public Health Service, varenicline is 
  recommended as a well-tolerated and effective first-line 
treatment option for smoking cessation. We should note 
that the majority of published clinical trials of the efficacy 
and tolerability of varenicline have generally excluded 
  smokers with comorbid conditions (ie, psychiatric disor-
ders, cardiovascular diseases), obese patients, adolescents, 
  pregnant women, and light smokers (10 cigarettes/d), 
which may reduce the generalization of the results to the 
broad population of smokers. To date, almost all clinical 
  trials have been sponsored by the manufactures of var-
enicline, suggesting that potential clinician bias may also 
affect the results even when double-blind procedures are 
used. Thus, more clinical-trials and postmarketing data are 
needed to confirm its efficacy, safety, and tolerability. Given 
the growing evidence suggesting a possible association 
between varenicline and increased psychiatric symptoms 
and other severe injuries potentially relating to uncon-
sciousness, the FDA has issued special warning for the 
use of varenicline in patients with pre-existing psychiatric 
illnesses, and the Federal Motor Carrier Safety Administra-
tion and Federal Aviation Administration have banned the 
use of varenicline in pilots, air-traffic controllers, and truck 
and bus drivers.
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